nLife Therapeutics appoints Dr. Errol B. De Souza as

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
nLife Therapeutics appoints Dr. Errol B. De Souza as Executive Chairman

GRANADA, Spain, June 1, 2016 (GLOBE NEWSWIRE) -- nLife Therapeutics, an early-stage biopharmaceutical company leading developments in conjugated nucleic acids as therapeutic agents for central nervous system (CNS) and neuromuscular (NS) disorders, today announced the appointment of Dr. Errol B. De Souza, Ph.D. as executive chairman.

Dr. De Souza joined the team at nLife on April 19, 2016. He has been president and CEO at leading biopharmaceutical companies, including Biodel Inc., Archemix Corp., and Synaptic Pharmaceuticals. He was co-founder and chief scientific officer at Neurocrine Biosciences, senior vice president and U.S. site head of drug innovation and approval (R&D) at Aventis and director of CNS disease research at DuPont Merck.

Dr. De Souza serves or has served on the faculty of major U.S. universities, editorial boards, National Institutes of Health committees and boards of directors. He has raised capital in private and public environments and established multiple collaborations with large pharmaceutical companies.

nLife Therapeutics has developed a proprietary oligonucleotide delivery platform with strong IP protection. Oligonucleotides can be applied to un-druggable target proteins, allowing the development of therapies in diseases that might otherwise have no viable treatment.

The nLife gene silencing applications are validated in primate models for Parkinson's disease, and in rodent models for morbid obesity and major depression disorder. The technology is now being diversified from 'gene silencing' to broader 'non-viral gene therapy' applications.

In addition to managing and chairing the board of directors at nLife, Dr. De Souza will liaise with investors and management to develop and implement strategy, scientific direction and fundraising. Dr. De Souza said: "I appreciate the board's vote of confidence and look forward to working with the scientific team. The nLife platform is expanding from oligonucleotides in gene silencing using antisense and siRNA, toward new applications related to mRNA therapeutics and non-viral CRISPR/CAS9 gene editing."

nLife is in the process of raising a Series B financial round to support the expansion of the nLife technology platform. The CEO at nLife Therapeutics, Andres Montefeltro said: "Errol's leadership and experience will help us to create shareholder value through fundraising and to establish collaborations with major biotech and pharmaceutical companies to accelerate the application of our delivery platforms to target a wider range of neurodegenerative conditions."  ENDS

About Errol B. De Souza, Ph.D. (high res images available on request) Dr. De Souza was the president and chief executive officer of Biodel (Nasdaq: BIOD) a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes (March 2010 to January 2016). From April 2003 to January 2009, Dr. De Souza was president and chief executive officer of Archemix Corporation, a biopharmaceutical company focused on oligonucleotide aptamer therapeutics. From September 2002 to March 2003, he was president and chief executive officer and a director of Synaptic Pharmaceuticals. As a result of a merger effective March 2003, Synaptic Pharmaceuticals became a wholly-owned subsidiary of H. Lundbeck A/S, an international pharmaceutical company.

Prior to that (1998 - 2002), Dr. De Souza held senior management positions with Aventis, and its predecessor company Hoechst Marion Roussel Pharmaceuticals where he was senior vice president and site head of US Drug Innovation and Approval (R&D) with responsibilities for the discovery and development of drug candidates for central nervous system and immunological disorders through proof-of-concept (Phase 2) trials. He was co-founder and executive vice president of R&D at Neurocrine Biosciences, Inc (1992 - 1998) and Head of CNS Diseases Research at DuPont Merck (1990 - 1992). 

Dr. De Souza received his B.A. (Honors) in physiology and his Ph.D. in neuroendocrinology from the University of Toronto and he received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine. He has edited 6 books and is an author or co-author of approximately 300 original articles, chapters or reviews and 300 abstracts. 

His research has focused on the receptor mechanisms involved in coordinating brain-endocrine-immune responses to stress.  He is the recipient of numerous national and international awards including the 1990 Joseph Cochin Young Investigator Award of the Committee on Problems of Drug Dependence, the 1991 Jordi Folch-Pi Memorial Award of the American Society for Neurochemistry, the 1994 Curt Richter Award and the 2005 Service Award of the International Society of Psychoneuroendocrinology, the 1997 Daniel H. Efron Award of the American College of Neuropsychopharmacology and the 2005 Ernst & Young Entrepreneur of the Year (New England Biotech category). 

Dr. De Souza has served on the faculty of several universities including The Johns Hopkins University School of Medicine, University of Pennsylvania School of Medicine, the University of California at San Diego and Rutgers University. He serves or has served on several Editorial Boards and National Institutes of Health Committees as well as Board of Directors of several private and public companies including Bionomics Limited (Australian Exchange: BNO.AX), Catalyst Biosciences (Nasdaq: CBIO), IDEXX Laboratories (Nasdaq: IDXX), Palatin Technologies (AMEX: PTN), Neurocrine Biosciences (Nasdaq: NBIX), Synaptic Pharmaceuticals (Nasdaq: SNAP) and Targacept, Inc., (Nasdaq: TRGT).

About nLife Therapeutics and its nucleic acid delivery platform technology (images on request) nLife Therapeutics is leading the development of cell-specific oligonucleotides as therapeutic agents for central nervous system and neuromuscular disorders.

Oligonucleotides are short nucleic acid polymers designed to bind to specific complementary messenger RNA strands promoting their degradation, which produces a decrease in the levels of specific proteins that may contribute to diseases when they accumulate.

Selective delivery and cell-specific targeting are achieved by attaching small molecule chemical ligands to the oligonucleotide. The conjugated oligonucleotides can be applied to un-druggable target proteins and have potential as a disease-modifying therapy for a broad array of genetic disorders that might otherwise have no viable treatment option.

Founded in 2010 and based in Granada (Spain), nLife has raised a total of USD 11 million from private capital and USD 4 million in public grants since inception. The 'angel' investors include four Spanish VC's: Crossroad Biotech, Caixa Capital, Biomed Risk, Invercaria and HealthEquity.

Recent publications: http://doi.org/10.1038/mp.2015.80 - Molecular Psychiatry - May 2016  Ferrés-Coy, A., Galofré, M., Pilar-Cuellar, F., Vidal, R., Paz, V., Ruiz-Bronchal, E., et al. (2015). Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration. Further information - http://www.n-life.es

Media Liaison - BN1 communications Sarah Morgan | sarahbn1@hotmail.com | +44 (0)7789 956966

Errol B. De Souza http://hugin.info/172620/R/2016951/748226.jpg

HUG#2016951

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 60

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 20

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
MassMedia's Two PRSA Wins Put Campaign Strategy in Focus

Updated Category News Views 128

A pair of trophies is nice; the underlying work matters more. MassMedia picked up two honors at the 2026 PRSA Las Vegas Valley Chapter Pinnacle Awards, presented October 28 at Siena Golf Club. One was a Pinnacle Award in Community Relations for its Safe Teen Driving work with Sam & Ash Injury Law. The other was an Award of Excellence in Reputation and Brand Management for...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 146

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 130

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 196

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 144

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Airtel Money Upgrade Raises the Stakes in East Africa

Updated Category News Views 54

Mobile money lives or dies in the irritating little moments: a transfer that hangs, a menu that makes people punch five buttons too many, a merchant payment that simply will not clear. Airtel Money is attacking that friction in Malawi and Tanzania with an enhanced platform from Comviva, and this is more consequential than the usual software-refresh chest thumping. In...

Continue Reading

Top 5 Most Recently Viewed Articles

Qubic's Game-Changing Milestone in Proof of Work Innovation

Updated Category News Views 335

Revolutionizing Mining: Qubic's Major Milestone Qubic, a decentralized compute and AI Layer 1 protocol, has reached a significant milestone with the successful implementation of its Useful Proof of Work (uPoW) concept. By harnessing the potential of merge mining with Monero and Tari, Qubic is setting a new standard in the mining industry and redefining the dynamics of...

Continue Reading
Global Ship Lease's Strong Q3 2024 Performance and Future Outlook

Updated Category News Views 187

Global Ship Lease Reports Impressive Third Quarter of 2024 Global Ship Lease, Inc. (NYSE: GSL), a key player in the containership ownership market, has recently revealed its unaudited financial results for the third quarter of 2024, reflecting strong operational performance and strategic positioning in an evolving maritime landscape. Quarterly Highlights: A Solid...

Continue Reading
Silverfort's New Security Features Enhance Identity Protection

Updated Category News Views 210

Enhancing Identity Security with Silverfort's New Capabilities Silverfort has recently announced exciting advancements in its identity security solutions, solidifying its leadership within the emerging identity verification and identity protection (IVIP) market. The introduction of Access Intelligence and Identity Graph & Inventory empowers organizations to proactively...

Continue Reading
Gabelli Multimedia Trust Maintains Steady Monthly Dividends

Updated Category News Views 306

Gabelli Multimedia Trust's Commitment to Shareholders The Gabelli Multimedia Trust Inc. (NYSE: GGT), located in RYE, N.Y., has reaffirmed its commitment to provide regular monthly cash distributions for its shareholders. This initiative emphasizes the Fund's dedication to maintaining a stable income stream, reflecting its solid financial strategies aimed at long-term...

Continue Reading
Shabodi Launches NetAware 2.1 to Transform Network Applications

Updated Category News Views 170

Shabodi Unveils NetAware 2.1: A Game-Changer for Programmable Networks Shabodi has proudly announced the launch of its innovative platform, NetAware 2.1, marking another significant stride in the realm of programmable networks. This advanced version embodies Shabodi's commitment to enhancing network-aware applications, offering a suite of capabilities that empower...

Continue Reading